Under this light our results may stimulate further research in the specific field of cHL, including assessment patients who receive PD-1 blockade upfront and/or in earlier treatment lines, to clarify why the 'obesity paradox' does not seem to apply to this tumor that is other way exquisitely sensitive to PD-1 blockade. Here, PDCD1 is linked to obesity disorder.